Format

Send to

Choose Destination
Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17.

MUC1 immunotherapy.

Author information

1
Breast Cancer Biology Group, King's College London, Guy's Hospital, London SE1 9RT, UK.

Abstract

The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

PMID:
20635898
DOI:
10.2217/imt.10.17
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center